cisplatin,gemcitabine,nivolumab
bms
['gu ', 'mibc', 'nivolumab', 'cisplatin', 'hcrn,gu,16-257', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nivo', 'gemcitabine', 'bladder', 'arca, (-arcade)']
#gu23 great start to day 2 presents hcrn gu 16-257 gemcitabine/ cisplatin + nivolumab with selective bladder sparing in pts w #mibc:
- ccr of 43% - 2-year bladder-intact survival is achieved in the majority of patients with a ccr. 
GU Oncologist/Clinical Trials/ Experimental Therapeutics @UCD_Cancer @UCDavisHealth via @uofcincy @GoBEARCATS. Tweets= My opinions #RCC #ASCO #immunotherapy